Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of EOC202 plus nab-paclitaxel in HR-positive, HER2-negative advanced breast cancer after endocrine therapy progression
CTR20212981Phase 2Active
- Sponsor
- WuXi AppTec
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eftilagimod alpha in breast cancer, sponsored by WuXi AppTec. Started Nov 2021; status: active.
02
Drugs
eftilagimod alpha
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20212981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212981.